Vivanza Biosciences Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 530057
₹1.74
▲ 0.00 (0.00%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
27/100
Weak
Valuation
86/100
Undervalued
Momentum
45/100
Neutral

QVM read Cheap on its own multiples Quality Weak, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
13.4
Industry median 36.1 (152 companies)
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-46.3
Free Cash Flow
₹-1 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
300.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
73.10%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
998.61%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
663.16%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
16.88%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.13
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
2.34
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
3.21
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
1.59%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
3.14%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
0.87%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
2.06%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
15.14%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
8.55%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (2.34)
  • No Return on equity is 15% or more (8.6%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.0%
Low 1.7400 · High 1.7400
1W return
-3.3%
Low 1.7100 · High 1.8000
1M return
2.4%
Low 1.7000 · High 1.9000
52W return
-46.3%
Low 1.6500 · High 1.9900
Lifetime High ₹210.0000 (Nov. 1, 2021)
Lifetime Low ₹1.7000 (Aug. 31, 2026)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
1.8
10D
1.8
20D
1.9
50D
2.7
100D
4.2
200D
6.7

Delivery and volume

Day avg. delivery
86.2%
Week avg. delivery
93.0%
Month avg. delivery
93.3%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1.74
Pivot
First resistance1.74
Second resistance1.74
Third resistance1.74
First support1.74
Second support1.74
Third support1.74
Day RSI33.9
Day MFI55.8
Day MACD-0.19
Day MACD signal-0.26

Beta

1M1.40
3M1.10
1Y1.10
3Y0.40

Price change analysis

↑ 2.4%
Over 1 Month
LowHigh
1.701.90
↓ -46.3%
Over 3 Months
LowHigh
1.651.99
↓ -46.3%
Over 6 Months
LowHigh
1.651.99
↓ -46.3%
Over 1 Year
LowHigh
1.651.99
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 13.4 (own history: 24.9–41.1)
Undervalued (below its own historical PE range)
Revenue (June 30, 2026)
₹9 Cr
Net profit (June 30, 2026)
₹0 Cr
Basic EPS (June 30, 2026)
₹0.0400

Ranks #None of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter20.02%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 20.02% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
26 May 2025 JAGDISH LAL Bulk Sell 263,386 2.4500 BSE
6 Feb 2025 RAJ KUMAR BAID Bulk Sell 222,222 2.3900 BSE
8 Jan 2025 VISHAL CHINUBHAI SUTHAR HUF Bulk Buy 3,000 3.6000 BSE
8 Jan 2025 SWATI VISHAL SUTHAR Bulk Sell 243,859 3.6800 BSE
8 Jan 2025 BIBHAS BHAGWANDAS ASAR Bulk Sell 300,000 3.6100 BSE
8 Jan 2025 VISHAL CHINUBHAI SUTHAR HUF Bulk Sell 1,040,315 3.6700 BSE
1 Jan 2025 JITEN KUMAR BISWAS Bulk Buy 218,000 3.6900 BSE
27 Dec 2024 SWATI VISHAL SUTHAR Bulk Sell 264,209 3.4900 BSE
27 Dec 2024 KALPESH VITHALDAS RAMI Bulk Sell 329,783 3.4800 BSE
26 Dec 2024 KALPESH VITHALDAS RAMI Bulk Sell 25,100 3.2900 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Ivee Injectaa Ltd. to Vivanza Biosciences Limited

All corporate actions →

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
2 Oct 2026 Company Update Vivanza Biosciences Ltd - 530057 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
28 Sep 2026 Insider Trading / SAST Vivanza Biosciences Ltd - 530057 - Closure of Trading Window
12 Sep 2026 AGM/EGM Vivanza Biosciences Ltd - 530057 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
12 Sep 2026 AGM/EGM Vivanza Biosciences Ltd - 530057 - Shareholder Meeting / Postal Ballot-Outcome of AGM
11 Sep 2026 AGM/EGM Vivanza Biosciences Ltd - 530057 - Shareholder Meeting / Postal Ballot-Outcome of AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (16.9%)

Weaknesses

  • Low Return on Equity (8.6%)
  • Thin net profit margin (1.6%)
  • High financial leverage (Debt/Equity 2.34)

Opportunities

  • PE below 15 (13.4) relative to a typical growth business

Threats

  • Down 46.3% over the past year

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Vivanza Biosciences Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.